ANALYSIS OF PATHOGENETIC RELATIONS BETWEEN CLINICAL AND METABOLIC PARAMETERS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE ON THE BACKGROUND OF HYPERTENSION (42-47)

Список литературы: 1. Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. 2. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016, 64, 73–84. 3. Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. 4. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-863. 5. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379. 6. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421427. 7. Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. 8. Kumari RSP, Vipula VA, Reddy BS, Nagadeepa W, Reddy BLN. Predictors of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type-2 diabetes mellitus. Int J Med Sci Public Health 2017;6:372-376. 9. Schilcher I, Ledinski G, Radulović S, et al. Endothelial lipase increases antioxidative capacity of high-density lipoprotein. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(10):1363–1374. doi:10.1016/j.bbalip.2019.06.011 10. Junji Kobayashi. Which is the Best Predictor for the Development of Atherosclerosis Among Circulating Lipoprotein Lipase, Hepatic Lipase, and Endothelial Lipase?, Journal of Atherosclerosis and Thrombosis, 2019, Volume 26, Issue 9: 758-759. 11. Chalasani, N. , Younossi, Z. , Lavine, J. E., Charlton, M. , Cusi, K. , Rinella, M. , Harrison, S. A., Brunt, E. M. and Sanyal, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67: 328-357. doi:10.1002/hep.29367 12. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, Volume 64, Issue 6, 1388 – 1402. 13. Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension, European Heart Journal, Volume 39, Issue 33, 01 September 2018: 3021–3104. https://doi.org/10.1093/eurheartj/ehy339 14. Kotronen A, Peltonen M, Hakkarainen A et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology, vol. 137, no. 3: 865–872. 15. Sterling, R. K., Lissen, E. , Clumeck, N. , Sola, R. , Correa, M. C., Montaner, J. , S. Sulkowski, M. , Torriani, F. J., Dieterich, D. T., Thomas, D. L., Messinger, D. and Nelson, M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006, 43: 1317-1325. doi:10.1002/hep.21178 16. Department of Health. UK Chief Medical Officers’ Alcohol Guidelines Review: summary of the proposed new guidelines. London: Department of Health. 2016.